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Abstract
Background: Transcription factor Oct1 regulates multiple cellular processes. It is known to be phosphorylated during the
cell cycle and by stress, however the upstream kinases and downstream consequences are not well understood. One of
these modified forms, phosphorylated at S335, lacks the ability to bind DNA. Other modification states besides
phosphorylation have not been described.
Methodology/Principal Findings: We show that Oct1 is phosphorylated at S335 in the Oct1 DNA binding domain during M-
phase by the NIMA-related kinase Nek6. Phospho-Oct1 is also ubiquitinated. Phosphorylation excludes Oct1 from mitotic
chromatin. Instead, Oct1
pS335 concentrates at centrosomes, mitotic spindle poles, kinetochores and the midbody. Oct1
siRNA knockdown diminishes the signal at these locations. Both Oct1 ablation and overexpression result in abnormal
mitoses. S335 is important for the overexpression phenotype, implicating this residue in mitotic regulation. Oct1 depletion
causes defects in spindle morphogenesis in Xenopus egg extracts, establishing a mitosis-specific function of Oct1. Oct1
colocalizes with lamin B1 at the spindle poles and midbody. At the midbody, both proteins are mutually required to
correctly localize the other. We show that phospho-Oct1 is modified late in mitosis by non-canonical K11-linked
polyubiquitin chains. Ubiquitination requires the anaphase-promoting complex, and we further show that the anaphase-
promoting complex large subunit APC1 and Oct1
pS335 interact.
Conclusions/Significance: These findings reveal mechanistic coupling between Oct1 phosphorylation and ubquitination
during mitotic progression, and a role for Oct1 in mitosis.
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Introduction
The Oct1 (POU2F1) transcription factor is a potent regulator of
metabolism and tumorigenicity [1]. It is widely expressed [2,3]
and interacts with a number of proteins including poly (ADP-
ribose) polymerase-1 (PARP-1), an enzyme that becomes activated
by DNA damage and oxidative stress [4], BRCA1, a tumor
suppressor protein associated with the DNA damage response
[5,6], and lamin B, a component of the nuclear and spindle
matrices [7,8,9]. Oct1 is also a signal integrator that is
phosphorylated at multiple residues during the cell cycle and in
response to genotoxic and oxidative stress [10,11]. Some of these
phosphorylation events alter Oct1 DNA binding selectivity,
resulting in altered target gene occupancy [10]. Other phosphor-
ylation events have not been carefully studied.
One of the aforementioned phosphorylation events occurs at
Ser335 within the DNA binding domain. Ser335 mutation to
aspartic acid blocks Oct1 binding to all tested DNA recognition
sites [10], and Ser335 phosphorylation has been associated with
mitosis in mass screens [12,13,14]. Little is otherwise known
about the function of this modification. Here, we identify a
previously unknown role for this form of Oct1. Consistent with
the effects of S335 phosphorylation on Oct1 ability to bind
DNA, we find that phosphorylation excludes Oct1 from mitotic
chromosomes. Phospho-S335 Oct1 accumulates on centro-
somes, spindle pole bodies and kinetochores, with enrichment
lost at the anaphase-telophase transition. Late in mitosis the
remaining phosphorylated Oct1 is modified by non-canonical
K11-linked polyubiquitin chains and colocalizes with lamin B at
the midbody. We show that the phosphorylated form of Oct1
interacts with lamin B, and that RNAi knockdown of either
Oct1 or lamin B1 in HeLa cells eliminates the midbody
localization of the other protein. We implicate the anaphase-
promoting complex (APC) in Oct1 ubiquitination. Oct1 RNAi
in HeLa cells strongly reduces antibody localization to
centrosomes, spindle pole bodies and the midbody, and results
in mitotic abnormalities. Overexpression of wild-type Oct1 also
disrupts mitoses, resulting in improper chromosome condensa-
tion, multinucleated cells and micronuclei. Overexpressed
S335A mutant Oct1 does not disrupt mitosis to the same
extent, implicating phosphorylation of this residue in Oct1
regulation of mitotic functions.
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Phosphorylation of Oct1 at serine 335 during mitosis
To study the regulation and function of Oct1 phosphorylation
at serine 335 (Oct1
pS335), we generated a phospho-specific
polyclonal antibody. The peptide sequence used to generate the
antibody (EALNLS335FKNMC) aligns perfectly to the POU-
specific portion of the DNA binding domain of human Oct1, Oct2
and Oct11. This region is less conserved in other human POU
domain proteins and does not match any other protein sequences
in the non-redundant protein databases (not shown). The
predicted molecular weight of unmodified human Oct1 is
80 kDa, but the standard form migrates at ,90 kDa in denaturing
SDS-polyacrylamide gels. Initial characterization of the antibody
using HeLa whole cell extracts and Western blotting indicated the
presence of an intense band of high apparent molecular weight
(.200 kDa) in cells arrested in mitosis by nocodozole (Figure 1A,
lane 2, asterisk). A band was also present in mitotic cells
corresponding to the expected molecular weight of ,90 kDa
(black arrowhead), as were intermediate forms with apparent
molecular weights of ,180 kDa and ,130 kDa (black dot and red
arrow). A pan-Oct1 antibody (recognizing the C-terminus)
identified the same forms, albeit at different relative intensities,
with the two largest forms only found in mitotic cells (Figure 1A,
lane 4). This result suggests that the four observed species are
different forms of Oct1. No augmentation in Western blot signal
was observed using HeLa cells arrested in S-phase with
hydroxyurea (not shown), suggesting that the effects are specific
to mitosis.
We hypothesized that one or more of the high molecular weight
Oct1
pS335 bands represented ubiquitinated species. To test this
possibility, we immunoprecipitated Oct1 using the phospho-
specific antibody and performed Western blots for both ubiquitin
(Ub) and total Oct1. A band of the same size corresponding to the
high molecular weight form was observed in both cases (Figure 1B,
lanes 2 and 5, asterisk). The band was further enriched using
extracts from nocodozole arrested cells (lanes 3 and 6), indicating
the presence of an Oct1 population enriched in mitotic cells that is
simultaneously phosphorylated at S335 and ubiquitinated. A
similar result was obtained using denaturing conditions, indicating
that the phospho-specific antibody is not co-precipitating a
ubiquitinated protein of precisely the same apparent molecular
weight, but rather recognizes a phosphorylated, ubiquitinated
form of Oct1. These experiments also revealed that the high
molecular weight form of Oct1 consists of a ladder of bands
(Figure S1A).
To demonstrate that the form of Oct1 recognized by the
antibody is phosphorylated, we treated nocodozole-arrested HeLa
cell extracts with calf intestinal alkaline phosphatase (CIP), which
resulted in the strong diminution of the high molecular weight
form, as well as other Oct1 forms, but had no effect on total Oct1
(Figure 1C). No increase in band mobility was observed with the
pan-Oct1 antibody following CIP treatment, consistent with the
finding that that ubiquitination is also present on Oct1
pS335.
Similar loss of phospho-specific antibody signal with CIP
treatment was also observed using indirect immunofluorescence
(IF) assays (Figure S1B).
We examined phosphorylated Oct1 in HeLa cells using IF and
the anti-Oct1
pS335 antibody (Figure 2A). HeLa mitoses were
staged using DAPI and anti-a-tubulin. Oct1
pS335 staining in
interphase cells (Figure 2A, white arrows) was largely confined to
individual puncta, the most intense of which correspond to the site
of microtubule nucleation. Increased Oct1
pS335 signal at an intact
nuclear envelope was noted in prophase (yellow arrows). Early
mitotic cells also showed staining at two puncta suggestive of
duplicated centrosomes. Oct1
pS335 was enriched at the prophase
nuclear envelope (see prophase detail). Work of others has
associated Oct1 with the nuclear periphery [7,8,15]. At meta-
phase, the chromosomes become fully condensed, and Oct1
pS335
was largely excluded from DNA, except at small puncta consistent
with kinetochores. We corroborated spindle pole body and
centrosome localization in mitotic and interphase cells using c-
tubulin antibodies (Figure 2B and C), and kinetochore localization
using CLASP1 antibodies (Figure 2D).
Following chromatid separation, Oct1
pS335 becomes concen-
trated at the developing midzone/contractile ring in anaphase and
Figure 1. Oct1
pS335 is enriched in M-phase HeLa cells. (A) Whole cell extracts were prepared from normal or nocodozole-arrested HeLa cells.
10% polyacrylamide gels were Western blotted using anti-Oct1
pS335 or anti-pan-Oct1 (C-terminal) antibodies (Bethyl). Anti-GAPDH is shown as a
loading control. (B) HeLa cell whole cell extracts were immunoprecipitated with anti-Oct1
pS335 antibodies and Western blotted using pan-Ub or pan-
Oct1 antibodies. H.C.=immunoglobulin heavy chain. (C) Whole cell extracts from nocodozole-arrested HeLa cells were treated with calf intestinal
alkaline phosphatase (CIP), or mock-treated. Western blots using anti-Oct1
pS335 or anti-pan-Oct1 antibodies are shown.
doi:10.1371/journal.pone.0023872.g001
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late anaphase to telophase, detectable Oct1
pS335 was greatly
diminished with the exception of the midbody, where a
concentrated signal was retained throughout cytokinesis. No such
change was detected using pan-Oct1 antibodies (Figure S2),
indicating that the diminution of the phosphorylated form at the
anaphase-telophase transition is not the result of changes in total
Oct1. IF using pan-Oct1 antibodies showed similar concentrations
at spindle pole bodies and the midbody (Figure S2). Similar mitotic
staining patterns were also obtained using A549 lung adenocar-
cinoma cells (Figure S3), indicating that the pattern is not peculiar
to HeLa cells. A comparative analysis of Oct1
pS335 and the well-
established mitotic marker histone H3
pS10 [16] indicated that all
cells that stained for histone H3
p10 also stained strongly for
Oct1
pS335 (Figure S4).
Oct1 ablation is associated with abnormal mitoses
We transiently transfected HeLa cells with Oct1 siRNAs,
analyzing cells 48 hr post-transfection to determine whether the
staining patterns were specifically due to Oct1. Using Oct1-specific
but not control siRNAs , we observed mitotic cells lacking or with
significantly reduced Oct1
pS335 spindle pole body/midbody
staining (Figure 3A). In addition, nearly all (.90%) of the mitotic
cells with decreased Oct1 staining lost the normal pattern of a-
tubulin staining (Figure 3A). We confirmed the effect of transiently
transfected Oct1-specific siRNAs by Western blot (Figure 3B). We
also noted poor/abnormal chromosome segregation and other
mitotic irregularities associated with partial and complete Oct1
knockdown (Figure 3A and Figure S5). To quantify these
irregularities, we analyzed 668 total control siRNA and 164 total
Oct1-specific siRNA mitoses over three separate experiments.
There were fewer mitotic events in the Oct1-specific siRNA
condition and more dead/floating cells, suggesting that following
acute reductions in Oct1, a higher fraction of mitoses result in
apoptosis and/or mitotic catastrophe. We scored approximately
10% of live control mitotic events as abnormal, based on spindle
disorganization and chromosomal abnormalities (e.g., incomplete
condensation, DNA outside the metaphase plate). Using the same
criteria, approximately 60% of the Oct1 knockdown events were
abnormal (Figure 3C). These findings indicate that Oct1
contributes to accurate mitosis in HeLa cells.
We also examined mitoses in Oct1 deficient primary early-
passage murine fibroblasts. Oct1 protein and activity is undetect-
able in these cells in Western blotting and gel mobility shift assays
using nuclear extracts, although a small amount of residual protein
is observed upon enrichment by affinity purification [17]. No IF
signal was detected in Oct1 deficient MEFs using pan-Oct1
antibodies (not shown). Using the phospho-specific antibody, wild-
type fibroblasts displayed a similar, albeit less uniform, mitotic
staining pattern as HeLa cells. The signal was diminished but not
eliminated in Oct1
2/2 fibroblasts (Figure S6). These results
suggested the presence of a cross-reacting co-expressed POU
transcription factor in fibroblasts. Oct1 is the sole detectable
octamer DNA binding activity in MEFs [17]. We therefore
focused on non-octamer binding POU transcription factors with
capacity to cross-react. One murine protein, Pit-1/POU1F1,
contains a perfect match to the peptide sequence used to generate
the phospho-specific antibody. Western blotting using pan-Pit-1
antibodies indicated that Pit-1 was expressed in murine fibroblasts
but not HeLa cells (Figure S6). Either due to redundancy with Pit-
1 or other differences between HeLa cells and primary murine
fibroblasts, we observed more mild evidence of abnormal mitoses
in Oct1
2/2 fibroblasts, including occasional abnormal DNA
condensation and abnormal spindles. Analysis of DNA content
also revealed the presence of aneuploidy, and an increase in cells
with .4N DNA in Oct1
2/2 fibroblasts (Figure S6).
Overexpression of Oct1 results in abnormal mitoses
We tested the effect of overexpressed full-length FLAG-tagged
wild-type and S335A Oct1 in HeLa cells using transient
transfection. Overexpression of wild-type protein resulted in
significantly increased Oct1
pS335 staining, in particular the
generation of interphase Oct1
pS335–staining puncta, while little
change was observed using the S335A mutant (Figure S7). In
mitotic cells, overexpressed wild-type FLAG-Oct1 was also
excluded from mitotic chromatin and resulted in disorganized
mitotic microtubules as compared to adjacent untransfected
controls (Figure 3D). We also studied interphase cells, using lamin
B (B1+B2) antibodies to visualize the nuclear envelope. Adjacent
untransfected (FLAG-negative) HeLa cells served as an internal
control. Cells in which Oct1 was concentrated in particular areas
also displayed lamin B concentrations in the same areas (Figure 3E,
asterisks), consistent with a described interaction between the two
proteins [7,8,9]. Interphase cells overexpressing FLAG-Oct1
displayed increases in multinucleation and micronuclei. The
micronuclei contained FLAG-Oct1 (Figure 3E, and Figure S8).
S335A Mutant Oct1 was incapable of inducing micronuclei, and
displayed reduced capacity to induce multinucleated cells
(Figure 3F). Unlike wild-type Oct1, overexpressed S335A mutant
Oct1 also could be found at mitotic DNA (Figure 3G). This result
indicates that S335 is required for exclusion from mitotic
chromatin.
Nek6 phosphorylates Oct1 serine 335 during mitosis
Computational inspection of Oct1 using the phosphorylation
site database PHOSIDA (http://www.phosida.com/) identified a
consensus Nek6 kinase target site at S335. Nek6 is a NIMA-related
kinase required for normal mitosis in HeLa cells [18]. We tested
the ability of recombinant purified Nek6 to phosphorylate an Oct1
peptide containing S335 fused to recombinant glutathione S-
transferase (GST) in vitro. GST-peptide fusions with a mutated
target serine residue and a different kinase (Cdk7) were used as
controls. Nek6 but not Cdk7 robustly produced a reactive target
peptide, but generated no signal using mutant GST-fused peptides
(Figure 4A). We repeated these experiments using radiolabeled
ATP to demonstrate that Nek6 was not phosphorylating the
peptide at another position, and to show that full-length
recombinant Oct1 was phosphorylated by Nek6 (Figure S9).
The data are consistent with a model in which Nek6 phosphor-
ylates Oct1 during mitosis. To test this model, we transiently
transfected Nek6-specific and scrambled control siRNAs into
HeLa cells. At 72 hr post-transfection the knockdown was robust
(Figure 4B). We focused on mitotic events (rounded cells with
duplicated centrosomes and partially/fully condensed chromo-
somes). In early mitosis, Nek6 knockdown reduced the intensity
and uniformity of Oct1
pS335 staining and disrupted the organiza-
Figure 2. Mitotic Oct1
pS335 is associated with the spindle pole bodies and midbody. (A) IF images of mitotic HeLa cells are shown. Cells
were stained with anti-a-tubulin and anti-Oct1
pS335 antibodies, and with DAPI. Scale bar: 20 mM. White arrows show an interphase cell. Yellow arrows
show different mitotic stages. (B) Similar images, except c-tubulin antibodies were used. Cropped images of individual mitotic cells are shown. (C)
Similar images of interphase cells. (D) Detail of a metaphase HeLa cell IF image stained with CLASP-1 and Oct1
pS335 antibodies.
doi:10.1371/journal.pone.0023872.g002
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Nek6 knockdown also reduced the overall staining intensity, and
specifically ablated Oct1
pS335 detected at the midbody (right
panels). We quantified the degree of pan-Oct1 or Oct1
pS335 signal
intensity in all mitotic cells following control or Nek6 siRNA
transfection, observing an overall two-fold decrease in Oct1
pS335
but not pan-Oct1 in Nek6 but not control siRNA (Figure S9). We
overexpressed FLAG-tagged wild-type or catalytically inactive
mutant Nek6 [18] (plasmids a gift of A. Fry) to determine the effect
on Oct1 phosphorylation. Overexpression of wild-type but not
mutant Nek6 resulted in accumulation of diffuse Oct1
pS335 and
brighter Oct1
pS335 puncta localizing to interphase centrosomes
(Figure 4D). Moreover, additional Oct1
pS335 puncta in interphase,
and mis-localization of mitotic spindle poles, were observed.
Mitotic HeLa cells also showed increased Oct1
pS335, although the
baseline expression was higher (Figure 4E). These results indicate
that Oct1 S335 is a Nek6 target.
Oct1 is a component of the spindle matrix and
participates in a complex with lamin B1 at the midbody
Our results suggested that Oct1 recruitment to mitotic
structures is important for normal mitoses. We therefore
Figure 3. Modulation of Oct1 levels results in abnormal mitoses in HeLa cells. (A) IF images are shown of HeLa cells transiently transfected
with control or Oct1-specific siRNAs. Arrows indicate positions of disrupted spindle pole/midbody localization. Formaldehyde fixation was used. (B)
Western blot showing effect of transfected control and Oct1-specific siRNA on total Oct1 expression in cycling cells. Cells were cultured for 72 hr prior
to analysis. (C) Quantification of abnormal in HeLa cells treated with control and Oct1-specific siRNAs. Values represent averages from three
independent experiments. Error bars depict standard deviations. (D) IF images of HeLa cells transiently transfected with FLAG-Oct1. Transfected cells
were incubated for 48 hr prior to formaldehyde fixation and staining with anti-a-tubulin and anti-FLAG antibodies. Single mitotic cell images are
shown. (E) IF images are shown of interphase HeLa cells transiently transfected with FLAG-tagged wild-type Oct1. Cells were stained with DAPI, and
anti-FLAG and anti-lamin B (B1+B2) antibodies. Arrows indicate transfected cells. Asterisk indicates an area of specific Oct1 and lamin B co-
localization. Example cells showing multinucleated cells and micronuclei are shown. Scale bars indicate 20 mM. (F) Quantification of the frequency of
micronuclei and multinucleated cells in mock transfected, wild-type Oct1 transfected, and S335A transfected interphase HeLa cells. Error bars depict
standard deviations. (G) Similar experiment as (E) using cells transiently transfected with an Oct1 S335A point mutant made using site-directed
mutagenesis of the human cDNA. Top panels show mitotic HeLa cells stained with anti-FLAG and anti-a-tubulin antibodies. Bottom panels
substituted lamin B antibodies.
doi:10.1371/journal.pone.0023872.g003
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with Oct1 recruit it to these structures. Lamin B has been shown to
interact with Oct1 and can co-localize with Oct1 at the nuclear
envelope [7,8]. Lamin B is also present at a structure known as the
spindle matrix, and is required for proper spindle organization
[19]. We used antibodies against total lamin B1+B2 to observe
localization in HeLa mitoses. We observed substantial co-
localization between lamin B and Oct1
pS335. In particular, the
spindle poles and midbody were strongly stained with both
proteins (Figure 5A, asterisks).
To determine whether phosphorylated Oct1 and lamin B
interact, we performed co-immumoprecipitation experiments
using whole cell extracts from untreated or nocodozole-arrested
HeLa cells. As expected, immunoprecipitation with lamin B
antibodies enriched total Oct1 in cycling HeLa cells (Figure 5B,
lane 2, arrow). Equivalent enrichment was also observed M-phase
arrested cells (lane 3), indicating that even after nuclear envelope
breakdown the interaction between Oct1 and lamin B is
preserved. These data indicate that the known interaction between
Oct1 and lamin B1 can be extended to mitosis. Immunobloting
using Oct1
pS335 antibodies also uncovered an interaction between
mitotic phosphorylated Oct1 and lamin B 9 (lane 6, arrow). The
high molecular weight form of Oct1 enriched in mitosis interacted
only poorly with lamin B (lane 6, asterisk).
Prior studies in Xenopus have shown that lamin B helps to form
a network referred to as the spindle matrix during mitosis. This
structure associates with the spindle to help maintain spindle pole
focus and spindle shape. Mass spectrometry analyses revealed
that a number of transcription factors including Oct2, an Oct1
paralog, are present in isolated spindle matrix [19,20]. Spindle
matrix components can be isolated from Xenopus egg extracts
(XEE) using a spindle assembly assay stimulated by magnetic
beads coated with the mitotic kinase Aurora A [19,20]. The
beads function as potent microtubule nucleating and organizing
centers and efficiently organize spindle poles. We retrieved the
bead-associated spindles using a magnet (Figure 5C, ‘‘Spin-
down’’). Buffer containing nocodozole was used to depolymerize
spindle microtubules. The beads (Figure 5C, lane 3) and their
associated spindle matrix (lane 4) were separated from each other.
We identified a band corresponding to Oct1 in the spindle, beads,
and matrix preparations using pan-Oct1 antibodies. As expected,
most lamin B3, the major form of lamin B in XEE, was present in
the spindle matrix (Figure 5C, lane 4). The presence of Oct1 in
the beads and the spindle matrix is consistent with the idea that
subsets of Oct1 are associated with the spindle poles and
surrounding matrix. We visualized the bead preparations and
the associated matrix using fluorescence microscopy. Robust
levels of Oct1 associated with the beads themselves as well as the
associated matrix (Figure 5D).
The above result suggested that loss of Xenopus Oct1 could have
functional effects in this assay, although there is a distinct
possibility of redundancy with the Oct2 protein. To test this
prediction, we immunodepleted Oct1 from XEE and reconstituted
the assay. Overall Oct1 immunodepletion was estimated at ,85%
based on band intensity, although the antibody showed some
variation in the ability to immunodeplete different Oct1 species
(Figure 5E). Immunodepleted extracts successfully reconstituted
mitotic spindle structures, however there was a statistically
significant defect in ability to form normal bipolar spindle
structures relative to mock-depleted extracts, and a corresponding
increase in aberrant monopolar structures (Figure 5F–G).
We expressed Oct1 fused to GFP in MEFs and used anti-GFP
coupled beads to identify associated proteins via mass spectrom-
etry (unpublished data). One of the identified proteins was Cdk11
(not shown), which regulates mitotic spindle stability. Cdk11
depletion results in similar in vitro defects in spindle assembly [21],
suggesting that Cdk11 co-depletion may contribute to the
phenotype. We therefore performed co-immunoprecipitation with
endogenous Oct1 and Cdk11 to confirm this interaction. Whole
cell extracts from nocodozole-arrested HeLa cells were precipitat-
ed using anti-Oct1
pS335 and Western blotted using Cdk11 and
control pan-Oct1 antibodies (Figure 5H). The results identify an
interaction with the known mitotic regulator Cdk11 and Oct1,
confirming the mass spectrometry and extending the interaction to
the native protein.
We next silenced lamin B1 using siRNAs and monitored
Oct1
pS335 localization during metaphase and anaphase. Lamin
B1 silencing did not change Oct1 protein levels, but resulted in
early mitotic defects such as mitotic spindle disruption and
unfocused spindle poles (Figure S10), as reported previously [19].
Phospho-Oct1 localization to both kinetochores and spindle poles
remained intact, suggesting that lamin B1 is not required for
Oct1 localization to these two structures. However, interestingly
in late mitosis Oct1 midbody localization was abolished
(Figure 5I). This result suggested that lamin B1 localizes
phosphorylated Oct1 to the midbody. To study the interaction
of Oct1 and lamin B at the midbody, we knocked down Oct1 and
lamin B1 in HeLa cells, and stained with lamin B (B1+B2) and
Oct1
pS335 antibodies. Control-siRNA transfected HeLa cells
showed expected concentrations of lamin B and Oct1
pS335 at
the midbody (Figure 5J, top panel and detail at right). Due to the
presence of lamin B2, total lamin B staining was minimally
affected, however lamin B concentration at the midbody was
largely eliminated (Figure 5J, middle panels), indicating that
midbody lamin B consists mostly of lamin B1 in HeLa cells. In
the lamin B1 knockdown condition, Oct1
pS335 midbody staining
was also absent in 50% of cells undergoing cytokinesis and
significantly depleted in others (detail at right), suggesting that
lamin B1 recruits phospho-Oct1. Oct1 knockdown (lower panels)
also quantitatively depleted lamin B1+B2 at the midbody. These
findings indicate that during cytokinesis lamin B1 and Oct1 are
mutually required for midbody localization.
Figure 4. Nek6 contributes to mitotic Oct1 phosphorylation at S335. (A) In vitro kinase assay using purified recombinant Nek6 or Cdk7, and
GST fused to wild-type or mutant Ser335 target peptide sequences. A Coomassie blue-stained SDS-polyacrylamide gel is also shown to confirm
presence of the purified peptide. (B) Nek6 knockdown in HeLa cells. A Western blot using anti-Nek6-specific antibodies is shown. Extracts were
prepared 72 hr post-transfection. (C) HeLa cells were transfected with scrambled and Nek6-specific siRNAs, incubated for 72 hr, fixed and stained
with DAPI, anti-a-tubulin and anti-Oct1
pS335 antibodies. Examples of early (left) and late (right) mitoses are shown. Early mitotic percentages reflect
the number of events showing strong Oct1
pS335 staining (42/48 in the control vs. 21/47 in the Nek6 specific knockdown). Telophase percentages
reflect the number of events showing strong midbody staining (33/41 vs. 11/39). Formaldehyde fixation was used. (D) HeLa cells were transiently
transfected with FLAG-tagged wild-type Nek6 or catalytically inactive mutants (K75M), incubated for 24 hr, and prepared as in (B). Examples of
interphase cells are shown. Arrows indicate transfected (FLAG-positive) cells. Where two (yellow and white) arrows are present, two adjacent
transfected cells are shown. Formaldehyde fixation was used. (E) Mitotic examples. Arrows indicate examples of spindle poles that are more strongly
stained with anti-phospho-Oct1 when Nek6 is over-expressed. Formaldehyde fixation was used.
doi:10.1371/journal.pone.0023872.g004
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PLoS ONE | www.plosone.org 7 August 2011 | Volume 6 | Issue 8 | e23872Figure 5. Oct1 is present in the spindle matrix and forms a complex with lamin B1 at the midbody in HeLa cells. (A) Association of
phosphorylated Oct1 with lamin B at the centrosomes and midbody. HeLa cells were fixed and stained with antibodies against lamin B1+B2 and
Oct1
pS335. Mitotic stage is on the left. Asterisk indicates the midbody structure. (B) Whole cell extracts from cycling HeLa cells and cells arrested in M-
phase using nocodozole were immunoprecipitated using mouse anti-lamin B antibodies. Left panel shows a Western blot using pan-Oct1 antibodies.
Black arrow shows predicted Oct1 molecular weight. Asterisk shows the high molecular weight form identified in Fig. 1. Right panel: the blot was
stripped and re-probed using Oct1
pS335 antibodies. (C) Spindle matrix preparations generated from Xenopus oocyte extracts (XEE, lane 1) were
Western blotted using pan-Oct1, lamin B3, and a-tubulin antibodies. (D) IF images of bead spindown preparation. Pan-Oct1 antibodies, and
rhodamine-conjugated a-tubulin were used. (E) Xenopus Oct1 was immunodepleted using magnetic protein A-coupled beads (see methods). Oct1
Oct1 in Mitosis
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pS335 is modified by K11-linked poly-Ub
chains associated with the midbody
Our data suggested that there are qualitative differences
between Oct1
pS335 midbody localization and localization to other
mitotic structures: midbody association is maintained after most
signal is eliminated (Figure 2A), and lamin B is required for
Oct1
pS335 midbody localization but not localization to other
structures (Figure 5F–H). We therefore sought biochemical
correlates that may underlie these differences. Proteins modified
by non-canonical K11-linked poly-Ub chains are enriched in the
midbody [22]. We tested whether Oct1 is modified through K11-
linked poly-Ub chains (K11-Ub) using a specific antibody [22].
Although Oct1 is ubiquitinated in cycling or nocodozole-arrested
HeLa cells (Figure 1C), immunoprecipitation of phospho-Oct1
from these cells and Western blotting using K11-Ub antibodies
produced little evidence of Oct1 K11-linked ubiquitination (not
shown). K11 accumulates late in mitosis [22] suggesting that Oct1
may be modified by canonical Ub early in mitosis, but switches to
a K11-linked form at later stages. We therefore arrested cells in
G1/S with thymidine, released them from the thymidine block
and arrested them in mitosis with nocodozole. Following release
from nocodozole arrest, K11-Ub linkages were detectable after
two hours (Figure 6A). Under the same conditions, immunopre-
cipitated Oct1
pS335 was associated with K11-Ub as assessed by
Western blot (Figure 6A, lower panels). To confirm this finding, we
co-stained HeLa cells with the Oct1
pS335 and K11-Ub antibodies
and examined late stage mitoses (Figure 6B). In metaphase, both
K11-Ub and Oct1
pS335 were excluded from mitotic chromatin,
however the two antibody signals displayed little overlap. For
example, no K11-Ub was detected in the spindle poles. Telophase
cells showed co-localization to the developing midbody, however
the two signals remained spatially distinct, with K11-Ub flanking
the more centrally localized Oct1
pS335 (Figure 6B, see inset detail
at left). In contrast, cells late in cytokinesis showed tight spatial
overlap at the midbody.
The above results are consistent with models in which Oct1
K11-Ub occurs exclusively late in mitosis, or in which Oct1 is
continually modified but is rapidly degraded, with degradation
slowing or ending at late mitosis. To distinguish these two
possibilities, we treated 24 hr nocodozole-arrested HeLa cells with
the proteosome inhibitor MG132 during the final 6 hr. Nocodo-
zole-arrested cells showed some evidence of Oct1
pS335 K11-Ub
(Figure 6C, lane 1), presumably because the nocodozole arrest was
less precise than that in Figure 6A using a thymidine block. As
expected, MG132 treatment caused total K11-Ub-modified
proteins to accumulate (lane 4). In addition, the higher molecular
weight forms of phosphorylated Oct1 were increased while the
lower molecular weight forms were unaffected (Figure 6C, lane 2).
These results indicate that Oct1 ubiquitinated species can be
enriched by proteasome inhibition. Using IF, we found that
mitotic HeLa cells treated with MG132 showed K11-Ub
colocalization with Oct1
pS335 at the spindle poles (Figure 6D).
Mitotic cells treated with MG132 also showed larger spindle pole
puncta (compare Figure 6D with Figure 6B). We therefore
immunoprecipitated Oct1
pS335 from extracts of nocodozole/
MG132-treated HeLa cells. Treatment with MG132 increased
total and K11-specific Oct1
pS335 ubiquitination (Figure 6E, lanes 2
and 5). These results are consistent with a model in which
Oct1
pS335 undergoes cycles of K11 ubiquitination and destruction
throughout mitosis, except at later stages when the protein is
stabilized and detectable.
One activity known to catalyze K11-linked ubiquitination is the
anaphase promoting complex/cyclosome (APC/C) [22,23,24]. To
test whether Oct1 and APC/C interact, we performed co-
immunoprecipitation using anti-Oct1
pS335 and extracts from
mitotic HeLa cells. Western blotting revealed the presence of
not only Oct1 but also the APC/C large subunit APC1 in the
immunoprecipitate (Figure 6F). To demonstrate a causal connec-
tion, we knocked down Fzr1, which encodes the APC/C
component Cdh1, using siRNAs [22]. Fzr1 mRNA (not shown)
and APC/C
Cdh1 protein (Figure 6G) was efficiently ablated in
mitotic-arrested HeLa cells. Specific but not control siRNA
transfection significantly attenuated the high molecular weight
phosphorylated form of Oct1 (Figure 6H). Further, Cdh1
knockdown attenuated several ubiquitinated Oct1
pS335 forms in
nocodozole-arrested, MG132-treated HeLa cells, as measured by
Oct1
pS335 immunoprecipitation followed by Western blotting with
pan-Ub or K11-Ub antibodies (Figure 6I, lane 3), including a
K11-Ub-modified species (lane 6). The degree of specific K11-Ub
reduction averaged 37% in these experiments (not shown). Lastly,
Cdh1 knockdown eliminated the ability of MG132 to redistribute
K11-Ub signal to sites of Oct1 phosphorylation, implicating the
APC in the deposition of K11-Ub at phosphorylated Oct1 that can
be visualized when proteasome degradation is blocked (Figure
S11).
Discussion
Here we show that Oct1 phosphorylated at position S335 by
Nek6 is ubiquitinated and associates with mitotic structures.
Oct1
pS335 is displaced from mitotic chromatin and concentrated at
spindle pole bodies and the midbody during mitosis. Interphase
cells show Oct1
pS335 staining at centrosomes. The signal detected
during mitosis is qualitatively different from that observed during
interphase, and cannot be explained simply by increased total
Oct1 levels. With the exception of the midbody, Oct1
pS335 staining
is rapidly lost at the anaphase-telophase transition. We identify
Nek6 is an upstream Oct1
pS335 kinase. Previous studies have
shown that Nek6 localizes to the centrosomes in interphase cells,
and to the spindle poles and midbody during mitosis. Nek6 loss of
function also results in mitotic abnormalities and apoptosis in
HeLa cells [18]. The activities of Oct1-associated proteins are
consistent with these findings. For example, the DNA damage
sensing factor BRCA1 is known to interact with Oct1 [5,6] and is
a known mitotic regulator that localizes to centrosomes [25,26,27].
PARP-1 also interacts with Oct1 [4] and localizes to centrosomes.
PARP-1 is important for centrosomal function, including limiting
their duplication [28].
Western blots are shown of the non-specific and Oct1-specific depletions. a-tubulin is shown as a loading control. (F) Examples of spindle structures
generated using the depleted extracts. Images of structures conforming to the scoring criteria used in (G) are shown. (G) Quantification of spindle
structures using non-specific of Oct1-specific depletion. Error bars depict standard error of the mean. (H) Co-immunoprecipitation Cdk11 with
endogenous phospho-Oct1. Mitotic-arrested HeLa whole cell extracts were immunprecipitated using phospho-Oct1 antibodies and probed with anti-
Cdk11 or anti-pan-Oct1. Arrest was accomplished with 18 hr treatment with nocodozole. (I) HeLa cells were transiently transfected with Lamin B1-
specific siRNAs. Cells were incubated for 72 hr, fixed and stained with a-tubulin and pS335 antibodies. Images of cells undergoing abcission are
shown. Formaldehyde fixation was used. (J) HeLa cells transfected with control siRNAs, or siRNAs against Oct1 or lamin B1 were fixed and stained
with lamin B and Oct1
pS335 antibodies. IF images of mitotic HeLa cells undergoing abcission are shown. Arrow indicates position of the midbody.
Detail at right shows isolated midbody structures. Formaldehyde fixation was used.
doi:10.1371/journal.pone.0023872.g005
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the context of the cell cycle. Mitotic phosphorylation was
described at a different residue, S385 [11]. S385 phosphorylation
was found to be cell cycle dependent and mediated by PKA. It was
also noted that Oct1 purified from M-phase cells did not bind to
DNA [29]. Later it was shown that Oct1 is excluded from mitotic
chromatin [30]. Recent screens [12,13,14] identified enrichment
in both Oct1 S335 and S385 phosphorylation during M-phase.
We found that phosphorylation at S385 does not block DNA
binding but instead alters the Oct1 selectivity for different DNA
binding configurations [10]. We postulate that S385 phosphory-
lation correlates with S335 phosphorylation in mitosis, but that it is
S335 phosphorylation that causes Oct1 exclusion from mitotic
chromosomes. We substantiated this hypothesis by showing that
overexpressed FLAG-tagged Oct1 is excluded from mitotic DNA
while Oct1 with a S335A mutation is not.
Figure 6. Dynamic ubiquitination of Oct1 during mitosis. (A) HeLa cells were blocked in G1 with thymidine, released and arrested in mitosis
using 0.1 mM nocodozole as described [22]. Top panels show Western blot with K11-Ub and pan-Oct1 antibodies, and GAPDH antibodies as a loading
control, from cells arrested with nocozole or following 2 hr release from nocozole. For the bottom panels, samples were immunoprecipitated using
anti-Oct1
pS335 antibodies, and probed with antibodies against pan-Ub, K11-Ub and pan-Oct1. H.C.=immunoglobulin heavy chain. (B) IF images of
HeLa mitoses stained with Oct1
pS335 and K11-Ub antibodies. Two metaphase, telophase and late cytokinesis examples are shown. Merged images
from the two latter cases also show detail of the midbody structure (inset). (C) HeLa cells were arrested with nocodozole (0.5 mM) for 18 hr, and then
incubated with MG132 for a further 6 hr. Whole cell extracts were prepared and subjected to Western blotting using Oct1
pS335 and K11-Ub
antibodies. (D) HeLa cells were treated with MG132, fixed and subjected to IF using K11-Ub and Oct1
pS335 antibodies. Detail of metaphase cells is
shown. (E) Whole cell extracts from HeLa cells arrested as above were immunoprecipitated with anti-Oct1
pS335 antibodies and Western blotted using
pan-Ub, K11-Ub or pan-Oct1 antibodies. H.C.=immunoglobulin heavy chain. (F) Nocodozole-arrested HeLa whole cell extracts were
immunoprecipitated using Oct1
pS335 antibodies and probed using pan-Oct1 or APC1 (AbCam). (G) Verification of Cdh1 knockdown. HeLa cells
were transfected with Cdh1 siRNAs for 48 hr, after which cells were treated with 0.5 mM nocodozole for 18 hr. A Western blot is shown using Cdh1
antibodies. GAPDH is shown as a loading control. (H) HeLa cells were transfected with Cdh1 siRNAs. 24 hr-post transfection, cells were treated with
0.5 mM nocodozole. 42 hr-post transfection, cells were treated with MG132 for 6 hr. Whole cell extracts were prepared after 48 hr. (I) siRNA-
transfected HeLa cells as in (H) were immunoprecipitated using Oct1
pS335 antibodies and Western blotted using pan-Ub or K11-Ub antibodies.
doi:10.1371/journal.pone.0023872.g006
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pS335 is also ubiquitinated, including by non-canonical K11-
Ub late in mitosis. Ubiquitinated proteins have been previously
associated with the spindle pole bodies and midbody [31,32].
Although we found that K11-Ub-modified Oct1 was detectable
only in late mitoses in normal HeLa cells, cells treated with the
proteasome inhibitor MG132 accumulated K11-Ub at structures to
which Oct1 localizes in early mitotic stages. This result suggests a
model in which K11-Ub modified Oct1
pS335 is formed throughout
mitosis, but is degraded rapidly prior to telophase, at which time
degradation slows or stops. A model for Oct1 phosphorylation and
ubiquitination through the cell cycle is shown in Figure 7. APC
interacts with Oct1 and is required for Oct1 K11 ubiquitination,
strongly suggesting that APC is the upstream Oct1 Ub ligase. We
observe these interactions and activities outside of anaphase,
however it is widely recognized that the APC is active throughout
the cell cycle, including in early mitosis [33].
Although a simple model is that Oct1 is phosphorylated at S335
and becomes non-functional, several lines of evidence suggest that
Oct1
pS335 acquires new functions. In Xenopus egg extracts, Oct1
co-purifies with the spindle matrix, which helps maintain spindle
shape. Oct1 also localizes with lamin B at the midbody. Lamin B1
and Oct1 are mutually required to localize each other to the
midbody, suggesting that they form a complex. Aside from the
specific localization to mitotic structures, results from both Oct1
loss- and gain-of-function experiments implicate Oct1 as a mitotic
regulator, at least in some cell types. For example, the organization
of the mitotic spindle is disrupted upon Oct1 siRNA knockdown in
HeLa cells. In XEE, Oct1 depletion causes defects in spindle
morphogenesis, implicating Oct1 in mitosis-specific functions.
Based on the observed Oct1 localization patterns, it is likely that
the mitotic irregularities caused by changes in Oct1 levels are
directly associated with mitotic regulation. Furthermore, an intact
serine at position 335 is important for the mitotic phenotype of
over-expressed Oct1, implicating this residue in mitotic functions.
We found that Oct1 is not required for the completion of mitosis in
HeLa cells but rather appears to play a regulatory role. In other cell
types, such as murine fibroblasts and A549 cells, the effect of Oct1 is
more mild than in HeLa cells. Oct1 deficient embryos survive past
gastrulation [17,34] and Oct1 deficient MEFs proliferate normally in
culture [1,17]. Primary Oct1 deficient MEFs undergo oncogenic
transformation poorly relative to wild-type controls, but immortalize
normallyby serial passage [1]. In this sense, the role of Oct1 inmitosis
may be more akin to BRCA1, which appears to act as a mitotic
regulator rather than a core component of the mitotic machinery
[25,26,27]. As a second example, lamin-B RNAi results in a delay in
prometaphase, following which cells can finish mitosis [19].
Figure 7. Model for Oct1 localization and modification through the cell cycle. Oct1 occupies sites in the DNA and regulates gene
expression during interphase. Oct1
pS335 localizes to centrosomes. Early in mitosis Oct1 is phosphorylated by Nek6 and localizes to spindle pole bodies
and kinetochores. Oct1 is also ubiquitinated. Oct1 modified through non-canonical K11-linked Ub chains is rapidly degraded by the proteasome and
is not readily detectable unless degradation by the proteasome is inhibited. Late in mitosis the bulk of phosphorylated Oct1 is de-phosphorylated,
with the remaining phosphorylated Oct1 concentrated at the midbody. K11-Ub is readily detectable at the midbody, presumably because
degradation has slowed or stopped. Following abcission the remaining phosphorylated Oct1 is de-phosphorylated, degraded or relocated to the
centrosome.
doi:10.1371/journal.pone.0023872.g007
Oct1 in Mitosis
PLoS ONE | www.plosone.org 11 August 2011 | Volume 6 | Issue 8 | e23872Methods
Tissue Culture
Oct1 deficient MEFs have been described previously [17]. HeLa
cells (ATCC)werearrested inM-phase using 0.5 mg/ml nocodozole
for 18 hr. Thymidine block and release from nocodozole were
performed identically to Matsumoto et al. [22]. MG132 (Calbio-
chem) was applied at 5 mM for 6 hr. For experiments using both
nocodozole and MG132, cells were treated with nocodozole for
12 hr, following which MG132 was added at 5 mM and cells were
incubated with nocodozole and MG132 for a further 6 hr. Cells
were maintained in a humidified environment at 37uC with 5%
CO2. HeLa cells were transiently transfected using polyethylenei-
mine (PEI, Sigma) and pCG-FLAG-Oct1 [35,36] or S335 mutant
Oct1 generated as described [10].
Antibodies
A commercial rabbit phospho-specific antibody (Bethyl) was
raised against the peptide EALNLS335FKNMC. The antibody was
purified in two steps, first by blocking with unphosphorylated
peptide to remove non-phospho-specific antibodies, then by
affinity purification using the phosphorylated epitope. Mouse
antibodies against a-tubulin, c-tubulin, CLASP-1, lamin B, and
goat anti-Pit-1, were obtained from Santa Cruz. Mouse anti-pS10-
H3 was obtained from Cell Signaling, and mouse anti-glyceral-
dehyde 3-phosphate dehydrogenase (GAPDH) from Chemicon.
Rabbit anti-APC1 and mouse anti-Cdh1 antibodies were
purchased from Abcam. Mouse anti-FLAG and rabbit anti-Nek6
antibodies were from Sigma. For pan-Oct1, a rabbit antibody
(Bethyl) was used with the exception of Figure 1D, which used a
mouse antibody (Millipore). Rabbit anti-Ub antibodies were a gift
of M. Rechsteiner. Human anti-K11-Ub antibodies were a gift of
V. Dixit. Rabbit anti-Cdk11 was purchased from Bethyl.
Spindle matrix preparation
Assembly of spindles from Xenopus egg extracts using AuroraA-
conjugated beads was conducted as described [19]. For Oct1
immunodepletion, rabbit anti-Oct1 (Bethyl) or nonspecific IgG
control (Sigma) antibodies were used similarly to Goodman et al.
[37], except that 75 ml of magnetic protein A-Dynabead slurry was
used per 100 ml of extract.
Immunofluorescence
CoverslipswerecoatedwithPoly-L-lysine (Sigma)for30 minand
placed into6 well dishes where counted cells wereplated. Cells were
washed with phosphate buffered saline (PBS) two times prior to
fixation. Methanol fixation was performed as described [22]. For
formaldehyde fixation, cells were incubated in 4% formaldehyde in
CSK buffer (100 mM NaCl, 300 mM Sucrose and 10 mM PIPES
pH6.8) for 30 min at room temperature (RT), and washed three
times with CSK buffer plus protease inhibitor cocktail (PIs, Roche).
Permeabilization was achieved by adding CSK buffer (+0.5%
Triton-X-100 and PIs) for 10 min, followed by 3 washes with PBS-
T (PBS+0.05% Tween-20). IF images using K11-Ub, pan-Ub, and
pan-Oct1 antibodies used methanol fixation, while phospho-histone
H3 antibodies used formaldehyde. Antibodies against CLASP-1, a-
and c-tubulin, lamin B and phospho-S335 worked efficiently with
both fixation procedures. Fixed cells were blocked with IF buffer
(PBS-T with 1% donkey serum) for 1 hr at RT. Primary and
secondary antibodies diluted in the IF buffer and were incubated
sequentially. After each incubation, cells were washed with PBS-T
for 10 min. Stained coverslips were placed on slides using mounting
medium with DAPI (Vector). Images were taken using a Zeiss
Axioplan 2 imaging microscope with a 1006 oil immersion
objective and a numerical aperture of 1.3. Digital fluorescence
and DIC images were acquired using an AxioCam MRm
monochrome digital camera. Final images were processed, given
false color and merged using Photoshop CS3 (Adobe Systems). All
scale bars conform to 20 mM. Mitotic staging followed established
criteria, e.g. Maiato et al. [38] and Pereira et al. [39].
In Vitro Kinase Assay
Two sets of complimentary oligo DNA (S335 and A335) were
anealed and ligated into pGEX-4T1 (Promega) using a SmaI
restriction site. Expressed proteins in BL21 Codon-plus (Stratagene)
Escherichia coli transformed with each construct were purified using
glutathione-sepharose resin (GEHealthcare). Sequences were S335:
59GCGATTTGAAGCCTTGAACCTCAGCTTTAAGAACAT-
GTGCAAGTGA39,5 9TCACTTGCACATGTTCTTAAAGCT-
GAGGTTCAAGGCTTCAAATCGC39; A335: 59GCGATTT-
GAAGCCTTGAACCTCGCCTTTAAGAACATGTGCAAG-
TGA39,5 9TCACTTGCACATGTTCTTAAAGGCGAGGTTC-
AAGGCTTCAAATCGC39. The GST-fused peptide (WT, RF-
EALNLS335FKNMCK or S335A) were incubated with recombi-
nant Nek6 and CAK complex (cdk7/cyclin H/MAT1, Millipore).
Kinase activities were assayed with the purified substrate according
to a manufacturer’s protocol.
RNAi
siRNA pools targeting three different regions of Oct1 or Nek6
(Santa Cruz) were mixed with lipofectamine RNAi max (Invitro-
gen) and transiently transfected according to manufacturer’s
protocol. Control siRNAs were used in parallel and also purchased
from Santa Cruz. Cells were cultured for 3 days prior to analysis.
siRNA knockdown of CDH1 (gene symbol Fzr1) and control
transfections used siRNA pools (Dharmacon). Cells were cultured
for 48 hr prior to analysis.
Immunoprecipitation
Cells were lysed with 18 mM Hepes pH 7.9, 150 mM NaCL,
1 mM EDTA, 1 mM EGTA, 1% Triton-X-100, protease
inhibitors (Roche, PIs), and phosphatase inhibitors (Roche, PhIs).
500 mg of extract was incubated with 4 mg of antibody in IP buffer
(50 mM Tris pH8.0, 20% glycerol, 0.5 mM EDTA, 0.1% NP-40,
1 mM DTT, PIs and PhIs) overnight at 4uC. Protein-antibody
complexes were precipitated using magnetic beads (Activmotif)
and washed three times with IP buffer.
Supporting Information
Figure S1 Further characterization of the phospho-
specific antibody. (A) The phospho-specific antibody immuno-
precipitates ubiquitinated Oct1 under denaturing conditions. IP
was performed as described in the materials and methods, except
cells were lysed in the identical buffer but with 8 M urea. Upon
dilution the resulting bead incubation step contained 1.6 M urea
in buffer. (B) Immunofluorescence images are shown. Left and
right panels show early and late mitosis, respectively. NT=no
treatment. METHODS: samples were prepared as described in
the materials and methods, except fixed samples were treated with
CIP in CSK buffer at 30uC for 30 minutes.
(JPG)
Figure S2 Localization of total Oct1 in Mitotic HeLa
Cells. (A) Total Oct1 concentrates at spindle pole bodies and the
midbody, and is excluded from mitotic chromosomes. Immunoflu-
orescence images are shown. HeLa cells were fixed and stained with
antibodies against a-tubulin and pan-Oct1. Arrow indicates position
Oct1 in Mitosis
PLoS ONE | www.plosone.org 12 August 2011 | Volume 6 | Issue 8 | e23872of additional puncta not recognized by phospho-Oct1 antibodies. (B)
Pan-Oct1 antibodies recognizing different epitopes stain different
mitotic structures. Cells were fixed and stained as in (A). Arrows
indicate additional metaphase puncta of unknown etiology not
recognized by phospho-Oct1 antibodies. (C) Side-by-side images of
normal interphaseand mitotic HeLacells stained with phospho-Oct1
or pan-Oct1 antibodies. Cells were fixed as in (A).
(JPG)
Figure S3 Localization of Oct1 Phosphorylated at S335
to Mitotic A549 Lung Adenocarcinoma Cells. (A) Immu-
nofluorescence images are shown. Specific mitotic cell is
highlighted with an arrow. The cells were co-stained with
antibodies to alpha-tubulin and with DAPI. (B) Similar images
using anti-gamma-tubulin antibodies. Protocols were identical to
those summarized in the methods section.
(JPG)
Figure S4 Comparison of the Properties of Anti-
Oct1
p335 and Anti-Histone H3
S10 Antibodies. (A) Low-
magnification (2006) immunofluorescence images of HeLa cells
stained with antibodies against phospho-histone H3 and phospho-
Oct1
335. Arrows indicate mitotic cells. White arrows show cells in
earlier mitotic stages that co-stain with both antibodies. Yellow
arrows show examples of cells staining only with the phospho-335
and not phospho-histone antibody. (B) Immunofluorescence
images of mitotic HeLa cells stained with anti-Oct1
p335 and
anti-histone H3
S10 antibodies. Scale bar: 20 mM.
(JPG)
Figure S5 Effect of Oct1 siRNA knockdown on HeLa
cells stained with alpha- and gamma-tubulin antibodies.
(A) Additional examples of mitotic abnormalities in HeLa cells
treated with Oct1-specific siRNAs. Reference Fig. 3 for normal
mitotic and scrambled siRNA controls. (B) Similar to (A) except
anti-gamma tubulin antibodies were used. Mitotic examples are
shown.
(JPG)
Figure S6 Phospho-S335 IF Staining Pattern and Cell-
cycle Phenotype of Primary MEFs. (A) Immunofluorescence
images of mitotic stages from wild-type primary early-passage
MEFs. (B) Mitotic examples of Oct1
2/2 MEFs. These examples
could not be easily staged due to abnormalities. Note the reduced
pS335 staining. (C) Alignment of human Oct1 and mouse Oct1,
Oct2 and Pit-1. Alignment was generated using a Clustal W-based
algorithm within the Vector NTI software package. Lower panel
shows a Western blot of HeLa cells, wild-type and Oct1 deficient
fibroblasts. The Pit-1 antibody was obtained from Santa Cruz. (D)
Cell cycle profile of primary early passage Oct1 deficient MEFs
and wild-type littermate controls. Inset shows expanded view of
cells with super-4N DNA content.
(JPG)
Figure S7 Effect of WT and S335A Oct1 overexpression
on Oct1
pS335 in HeLa cells. IF images are shown of interphase
and HeLa cells transiently transfected with wild-type or S335A
mutant pCG-Oct1.
(JPG)
Figure S8 Ectopic Oct1 expression in HeLa cells
increases alpha-tubulin levels, and induces formation
of puncta containing alpha-tubulin but lacking DNA. IF
images are shown of interphase HeLa cells transiently transfected
as in Figure S7. Fixed cells were stained with DAPI and antibodies
against the FLAG epitope and a-tubulin. Scale bars indicate
20 mM.
(JPG)
Figure S9 Additional evidence that Nek6 phosphory-
lates Oct1. (A) Nek6 was knocked down in HeLa cells using
siRNAs as in Fig. 4C, but using rabbit anti-pan-Oct1 antibodies.
(B) Pan-Oct1 and phospho-Oct1 channel signal intensity was
analyzed following Nek6 knockdown using ImageJ software (NIH).
6 control and 7 Nek6 siRNA mitotic events were averaged in the
case of pan-Oct1, and 5 control and 5 Nek6 siRNA mitotic events
were averaged in the case of phopsho-Oct1. (C) GST-fused to the
substrate peptide was tested as an in vitro kinase target as in Fig. 4A
but using c-
32P-ATP. (D) Full-length, His6-tagged recombinant
Oct1 purified from E. coli was used. Right panel shows a
Coomassie-stained gel of the same material. ‘‘D Oct1’’ indicates
presumptive Oct1 deletion products that are also phosphorylated
species. METHODS: Recombinant C-terminal His6-tag Oct1 was
expressed and purified as described (Stro ¨m AC, et al., Nucleic Acids
Res. 1996 Jun 1;24(11):1981–6).
(JPG)
Figure S10 Additional evidence of mutual localization
mediated by lamin B1 and Oct1. (A) HeLa cells were
transiently transfected with siRNAs against lamin B1 (Santa Cruz),
incubated for 72 hr and Western blotted with antibodies against
lamin B1 or GAPDH as a loading control. (B) IF images are
shown of mitotic HeLa cells transiently transfected with control or
lamin B1 siRNAs, and stained with antibodies against lamin B
(B1+B2) and Oct1
pS335 antibodies. Arrows highlight elongated/
split spindle poles.
(JPG)
Figure S11 APC is responsible for the accumulation of
K11-Ub signal at sites of Oct1 phosphorylation upon
proteasome inhibition. HeLa cells were transiently transfected
with control siRNAs or siRNAs directed against the APC
component CDH1 (gene symbol Fzr1, Dharmacon), incubated
for 48 hr. After 42 hr, cells were treated with MG132 as described
in the materials section. Cells were then fixed and processed for IF.
For quantification, mitotic events were scored +/2 based on
concordance between Oct1
pS335 and K11-Ub staining.
(JPG)
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